Algeria vs Sweden: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Algeria
95.0%
in 2025
Sweden
95.0%
in 2025
Algeria rank
37th
Sweden rank
37th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Algeria
- Sweden
How they compare
Algeria currently reports 95.0% against 95.0% in Sweden, a difference of 0.0%.
Across all 18 years both countries report, Sweden has been ahead every year.
Algeria ranks 37th and Sweden ranks 37th of 192 countries.
Sweden has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Algeria | Sweden | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 79.0% | 79.0% | Sweden |
| 2010s | 32.8% | 97.5% | 64.7% | Sweden |
| 2020s | 84.8% | 95.2% | 10.3% | Sweden |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Algeria or Sweden?
- Algeria, at 95.0% against 95.0% in Sweden as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Algeria and Sweden?
- 0.0%, with Algeria ahead.
- How many years of comparable data are there for Algeria and Sweden?
- 18 years are reported by both, from 2008 to 2025.
- How do Algeria and Sweden rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Algeria ranks 37th and Sweden ranks 37th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.